核因子-κB受体及其配体信号通路在肿瘤中的表达及其研究进展

doi:10.3969/j.issn.1004-616x.2017.01.016

摘要/Abstract

摘要：

核因子-κB受体（RANK）及其配体（RANKL）在最近十几年得到广泛研究。RANK在正常细胞和肿瘤细胞中均能高频表达。RANKL在肿瘤微环境中经常被检测到，并且在骨的重塑和免疫过程中起着关键作用。研究表明RANK和RANKL共同参与了肿瘤发生发展过程的各个阶段。RANK-RANKL信号通路主要由3个因素调节，它们分别是骨保护素（OPG）、骨保护素配体和一个能够结合RANKL的膜受体（LGR4）。本文以肿瘤转移为重点，探讨RANK-RANKL信号通路在肿瘤侵袭和转移中的意义以及以RANK-RANKL为靶点治疗肿瘤的相关研究进展。

关键词: 核因子-κB受体, 配体, 肿瘤, 转移, 机制

中图分类号:

R73-3

胡向阳, 杜远立, 陈涛. 核因子-κB受体及其配体信号通路在肿瘤中的表达及其研究进展[J]. 癌变·畸变·突变, 2017, 29(1): 78-81.

参考文献

[1] LANDSKRON G,FUENTE M D L,THUWAJIT P,et al. Chronic inflammation and cytokines in the tumor microenvironment[J]. Res J Immunol,2014,2014(2):149185.

[2] YASUDA H. RANKL,a necessary chance for clinical application to osteoporosis and cancer-related bone diseases[J]. World J Orthop, 2013,4(4):207-217.

[3] WALSH M C,CHOI Y. Biology of the RANKL-RANK-OPG system in immunity,bone,and beyond[J]. Front Immunol,2014,5:511.

[4] LI J,QIAN Y,HAO W. Structural basis of signal transduction in the TNF receptor superfamily[J]. Adv Immunol,2012,119(2):135-153.

[5] WITTRANT Y,THEOLEYRE S,CHIPOY C,et al. RANKL/RANK/OPG:new therapeutic targets in bone tumours and associated osteolysis[J]. Biochim Biophys Acta,2004,1704(2):49-57.

[6] WONG B R,JOSIEN R,LEE S Y,et al. TRANCE (tumor necrosis factor[TNF]-related activation-induced cytokine),a new TNF family member predominantly expressed in T cells,is a dendritic cell specific survival factor[J]. J Exp Med,1997,186(12):2075-2080.

[7] THEOLEYRE S,WITTRANT Y,TAT S K,et al. The molecular triad OPG/RANK/RANKL:involvement in the orchestration of pathophysiological bone remodeling[J]. Cytokine Growth Factor Rev,2004, 15(6):457-475.

[8] LACEY D L,TIMMS E,TAN H L,et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation[J]. Cell,1998,93(2):165-176.

[9] RENEMA N,NAVET B,HEYMANN M F,et al. RANK-RANKL signalling in cancer[J]. Biosci Rep,2016,36(4):e366.

[10] ANDERSON D M,MARASKOVSKY E,BILLINGSLEY W L,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function[J]. Nature,1997,390(6656):175-179.

[11] ARAI F,MIYAMOTO T,OHNEDA O,et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors[J]. J Exp Med,1999,190(12):1741-1754.

[12] LI J,SAROSI I,YAN X Q,et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism[J]. Proc Natl Acad Sci USA,2000, 97(4):1566-1571.

[13] KODAIRA K,KODAIRA K,MIZUNO A,et al. Cloning and characterization of the gene encoding mouse osteoclast differentiation factor[J]. Gene,1999,230(1):121-127.

[14] IKEDA T,KASAI M,UTSUYAMA M,et al. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus[J]. Endocrinology, 2001,142(4):1419-1426.

[15] KARTSOGIANNIS V,ZHOU H,HORWOOD N J,et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues[J]. Bone,1999,25(5):525-534.

[16] COLLIN-OSDOBY P,ROTHE L,ANDERSON F,et al. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells,regulation by inflammatory cytokines, and role in human osteoclastogenesis[J]. J Biol Chem, 2001,276(23):20659-20672.

[17] MATSUZAKI K,UDAGAWA N,TAKAHASHI N,et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures[J]. Biochem Biophys Res Commun,1998,246(1):199-204.

[18] QUINN J M,ELLIOTT J,GILLESPIE M T,et al. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro[J]. Endocrinology,1998,139(10):4424-4427.

[19] HSU H,LACEY D L,DUNSTAN C R,et al. Tumor necrosis factor receptor member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand[J]. Proc Natl Acad Sci USA,1999,96(7):3540-3545.

[20] KONG Y Y,FEIGE U,SAROSI I,et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand[J]. Nature,1999,402(6759):304-309.

[21] TAKAYANAGI H. Osteoimmunology:shared mechanisms and crosstalk between the immune and bone systems[J]. Nat Rev Immunol,2007, 7(4):292-304.

[22] PFITZNER B M,BRANSTETTER D,LOIBL S,et al. RANK expression as a prognostic and predictive marker in breast cancer[J]. Breast Cancer Res Treat,2014,145(2):307-315.

[23] TRIEB K,WINDHAGER R. Receptor activator of nuclear factor kappaB expression is a prognostic factor in human osteosarcoma[J]. Oncol Lett,2015,10(3):1813-1815.

[24] PAPANASTASIOU A D,SIRINIAN C,KALOFONOS H P. Identi-fication of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing:implications in breast cancer cell survival and migration[J]. Breast Cancer Res,2012, 14(4):1-16.

[25] ROUX S,AMAZIT L,MEDURI G,et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone[J]. Am J Clin Pathol,2002,117(2):210-216.

[26] CHAWLA S,HENSHAW R,SEEGER L,et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone:interim analysis of an open-label,parallel-group,phase 2 study[J]. Lancet Oncol,2013,14(9):901-908.

[27] HOFBAUER L C,KUHNE C A,VIERECK V. The OPG/RANKL/RANK system in metabolic bone diseases[J]. J Musculoskelet Neuronal Interact,2004,4(3):268-275.

[28] MIN J K,KIM Y M,KIM Y M,et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand[J]. J Biol Chem,2003,278(41):39548-39557.

[29] MIN J K,CHO Y L,CHOI J H,et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability:impaired permeability and angiogenesis in eNOS-deficient mice[J]. Blood,2007,109(4):1495-1502.

[30] RAJU R,BALAKRISHNAN L,NANJAPPA V,et al. A compre-hensive manually curated reaction map of RANKL/RANK-signaling pathway[J]. Database(Oxford),2011, 2011(1):21.

[31] GALIBERT L,TOMETSKO M E,ANDERSON D M,et al. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB,a member of the TNFR superfamily[J]. J Biol Chem, 1999,273(51):34120-34127.

[32] JIN G,AKIYAMA T,KOGA T,et al. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis[J]. EMBO J,2005,24(4):790-799.

[33] SIMONET W S,LACEY D L,DUNSTAN C R,et al. Osteopro-tegerin:A novel secreted protein involved in the regulation of bone density[J]. Cell,1997,89(2):309-319.

[34] BAUD'HUIN M,DUPLOMB L,TELETCHEA S,et al. Osteoprotegerin:multiple partners for multiple functions[J]. Cytokine Growth Factor Rev,2013,24(5):401-409.

[35] DAVID E,BLANCHARD F,HEYMANN M F,et al. The bone niche of chondrosarcoma:a sanctuary for drug resistance,tumour growth and also a source of new therapeutic targets[J]. Sarcoma,2011,2011(3):932451.

[36] HOLEN I,CROUCHER P I,HAMDY F C,et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells[J]. Cancer Res,2002,62(6):1619-1623.

[37] LUO J,YANG Z,MA Y,et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption[J]. Nat Med,2016.

[38] STYRKARSDOTTIR U,THORLEIFSSON G,SULEM P,et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits[J]. Nature,2013,497(7450):517-520.

[39] ZHU Y B,XU L,CHEN M,et al. GPR48 promotes multiple cancer cell proliferation via activation of Wnt signaling[J]. Asian Pac J Cancer Prev,2013,14(8):4775-4778.

[40] ESPOSITO M,KANG Y. Targeting tumor-stromal interactions in bone metastasis[J]. Pharmacol Ther,2014,141(2):222-233.

[41] BEKKER P J,HOLLOWAY D,NAKANISHI A,et al. The effect of a single dose of osteoprotegerin in postmenopausal women[J]. J Bone Miner Res,2001,16(2):348-360.

[42] SANTINI D,PERRONE G,ROATO I,et al. Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases[J]. J Cell Physiol,2011,226(3):780-784.

[43] BEKKER P J,HOLLOWAY D L,RASMUSSEN A S,et al. A single-dose placebo-controlled study of AMG 162,a fully human monoclonal antibody to RANKL,in postmenopausal women[J]. J Bone Miner Res,2004,19(7):1059-1066.

[44] LAMOUREUX F,RICHARD P,WITTRANT Y,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma:blockade of the vicious cycle between tumor cell proliferation and bone resorption[J]. Cancer Res,2007,67(15):7308-7318.

[45] ZHENG Y,ZHOU H,FONG-YEE C,et al. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis[J]. Clin Exp Metastasis,2008,25(5):559-567.

[46] MILLER R E,JONES J C,TOMETSKO M,et al. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases[J]. J Thorac Oncol, 2014,9(3):345-354.